ANXA5 / Annexin Ⅴ / Annexin A5 Protein (Native)

Annexin A5 Protein Datasheet

ANXA5 / Annexin Ⅴ / Annexin A5 Protein Product Information

• Synonym: ANX5, ENX2, PP4
• Protein Construction: A DNA sequence encoding the human ANXA5 (P08758?) (Met 1-Asp 320 ) was expressed and purified.
• Source: Human
• Expression Host: E.coli

ANXA5 / Annexin Ⅴ / Annexin A5 Protein QC Testing

• Purity: > 90 % as determined by SDS-PAGE.
• Endotoxin: Please contact us for more information.
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Met 1
• Molecular Mass: The recombinant human ANXA5 consisting of 320 amino acids and has a calculated molecular mass of 35.9 KDa. It migrates as an 34 kDa band in SDS-PAGE under reducing conditions.
• Formulation: Lyophilized from 0.2μm filtered solution of 50mM Tris, 240mMNacl , pH 8.5
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.
• SDS-PAGE: ANXA5 / Annexin Ⅴ / Annexin A5 protein

ANXA5 / Annexin Ⅴ / Annexin A5 Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

ANXA5 / Annexin Ⅴ / Annexin A5 Protein Description

Annexin Ⅴ, also known as Annexin A5 (ANXA5), belongs to a family of Ca²⁺ binding proteins that undergo reversible Ca²⁺-dependent binding to phospholipids(PLs) that are located on the cytosolic face of the plasma membrane. They are abundant intracellular proteins, and several different annexin gene products are expressed in all mammalian cells examined to date. Antithrombotic effect exerted by Annexin A5 (ANXA5) is thought to be mediated mainly by forming a mechanical shield over phospholipids(PLs) reducing availability of PLs for coagulation reactions. However, more specific properties of ANXA5 might be of importance for its antithrombotic function. Such examples include downregulation of surface-expressed tissue factor(TF), as well as upregulation of urokinase-type plasminogen activator(uPA) by ANXA5. Also, interation of ANXA5 with ligands involved in hemostasis, such as sulfatide and heparin, has been demonstrated.

References

1. Cederholm A. et al., 2007, Ann N Y Acad Sci. 1108: 96-103.
2. Schlaepfer DD. et al., 1992, Biochemistry. 311886-91.
3. Vermes I. et al., 1995, J Immunol Methods. 184 (1): 39-51.